Fasiglifam/TAK-875, a selective GPR40 agonist, improves hyperglycemia in rats unresponsive to sulfonylureas and acts additively with sulfonylureas

Journal of Pharmacology and Experimental Therapeutics

Volumn 357, Issue 1, 2016, Pages 217-227

  Ito, Ryo ^a   Tsujihata, Yoshiyuki ^a   Suzuki, Masami ^a   Miyawaki, Kazumasa ^a   Matsuda, Kae ^a   Takeuchi, Koji ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; BENZOFURAN DERIVATIVE; G PROTEIN COUPLED RECEPTOR; G-PROTEIN-COUPLED RECEPTOR 40, RAT; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE BLOOD LEVEL; SULFONE; SULFONYLUREA DERIVATIVE; TAK-875;

AGONISTS; ANIMAL; BLOOD; DIABETES MELLITUS, EXPERIMENTAL; DRUG POTENTIATION; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; HYPERGLYCEMIA; MALE; METABOLISM; RAT; ZUCKER RAT;

ANIMALS; BENZOFURANS; BLOOD GLUCOSE; DIABETES MELLITUS, EXPERIMENTAL; DRUG SYNERGISM; GLUCOSE TOLERANCE TEST; GLYBURIDE; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, ZUCKER; RECEPTORS, G-PROTEIN-COUPLED; SULFONES; SULFONYLUREA COMPOUNDS;

EID: 84962617899     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.115.230730     Document Type: Article

References (50)

1. Anello M, Gilon P, and Henquin JC (1999) Alterations of insulin secretion from mouse islets treated with sulphonylureas: perturbations of Ca2+ regulation prevail over changes in insulin content. Br J Pharmacol 127:1883-1891.
2. Asakawa T, Moritoh Y, Kataoka O, Suzuki N, Takeuchi K, and Odaka H (2009) A novel dipeptidyl peptidase-4 inhibitor, alogliptin (SYR-322), is effective in diabetic rats with sulfonylurea-induced secondary failure. Life Sci 85:122-126.
3. Atkinson LL, McDonald-Dyck C, Benkoczi C, and Finegood DT (2008) Effect of chronic rosiglitazone, metformin and glyburide treatment on beta-cell mass, function and insulin sensitivity in mZDF rats. Diabetes Obes Metab 10:780-790.
4. Baggio LL, Kim JG, and Drucker DJ (2004) Chronic exposure to GLP-1R agonists promotes homologous GLP-1 receptor desensitization in vitro but does not attenuate GLP-1R-dependent glucose homeostasis in vivo. Diabetes 53(Suppl 3):S205-S214.
5. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, Eilert MM, Ellis C, Elshourbagy NA, Goetz AS, and Minnick DT, et al. (2003) The orphan G proteincoupled receptor GPR40 is activated by medium and long chain fatty acids. J Biol Chem 278:11303-11311.
6. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, Xie B, and Leifke E (2012) TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-1411.
7. Charpentier G (2002) Oral combination therapy for type 2 diabetes. Diabetes Metab Res Rev 18(Suppl 3):S70-S76.
8. De Rubertis FR and Craven P (1976) Effects of reduced ATP concent on hepatic responses to glucagon. Metabolism 25:57-67.
9. Drucker DJ (2007) Dipeptidyl peptidase-4 inhibition and the treatment of type 2 diabetes: preclinical biology and mechanisms of action. Diabetes Care 30:1335-1343.
10. Feng DD, Luo Z, Roh SG, Hernandez M, Tawadros N, Keating DJ, and Chen C (2006) Reduction in voltage-gated K+ currents in primary cultured rat pancreatic betacells by linoleic acids. Endocrinology 147:674-682.
11. Feng J, Zhang Z, Wallace MB, Stafford JA, Kaldor SW, Kassel DB, Navre M, Shi L, Skene RJ, and Asakawa T, et al. (2007) Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. J Med Chem 50:2297-2300.
12. Fujiwara K, Maekawa F, and Yada T (2005) Oleic acid interacts with GPR40 to induce Ca2+ signaling in rat islet beta-cells: mediation by PLC and L-type Ca2+ channel and link to insulin release. Am J Physiol Endocrinol Metab 289:E670-E677.
13. Gjoni T and Urwyler S (2008) Receptor activation involving positive allosteric modulation, unlike full agonism, does not result in GABAB receptor desensitization. Neuropharmacology 55:1293-1299.
14. Harmon JS, Gleason CE, Tanaka Y, Poitout V, and Robertson RP (2001) Antecedent hyperglycemia, not hyperlipidemia, is associated with increased islet triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes 50:2481-2486.
15. Hinke SA, Pauly RP, Ehses J, Kerridge P, Demuth HU, McIntosh CH, and Pederson RA (2000) Role of glucose in chronic desensitization of isolated rat islets and mouse insulinoma (betaTC-3) cells to glucose-dependent insulinotropic polypeptide. J Endocrinol 165:281-291.
16. Ito R, Tsujihata Y, Matsuda-Nagasumi K, Mori I, Negoro N, and Takeuchi K (2013) TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats. Br J Pharmacol 170:568-580.
17. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, Fukusumi S, Ogi K, Hosoya M, Tanaka Y, and Uejima H, et al. (2003) Free fatty acids regulate insulin secretion from pancreatic beta cells through GPR40. Nature 422:173-176.
18. Kaku K, Araki T, and Yoshinaka R (2013) Randomized, double-blind, dose-ranging study of TAK-875, a novel GPR40 agonist, in Japanese patients with inadequately controlled type 2 diabetes. Diabetes Care 36:245-250.
19. Kaku K, Enya K, Nakaya R, Ohira T, and Matsuno R (2015) Efficacy and safety of fasiglifam (TAK-875), a G protein-coupled receptor 40 agonist, in Japanese patients with type 2 diabetes inadequately controlled by diet and exercise: a randomized, double-blind, placebo-controlled, phase III trial. Diabetes Obes Metab 17:675-681.
20. Kawaki J, Nagashima K, Tanaka J, Miki T, Miyazaki M, Gonoi T, Mitsuhashi N, Nakajima N, Iwanaga T, and Yano H, et al. (1999) Unresponsiveness to glibenclamide during chronic treatment induced by reduction of ATP-sensitive K+ channel activity. Diabetes 48:2001-2006.
21. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, and Poitout V (2008) The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432-2437.
22. Kotarsky K, Nilsson NE, Flodgren E, Owman C, and Olde B (2003) A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem Biophys Res Commun 301:406-410.
23. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, Luo J, Lin DC, and Poitout V (2007) GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56:1087-1094.
24. Leahy JL (2005) Pathogenesis of type 2 diabetes mellitus. Arch Med Res 36:197-209.
25. Lee Y, Hirose H, Ohneda M, Johnson JH, McGarry JD, and Unger RH (1994) Betacell lipotoxicity in the pathogenesis of non-insulin-dependent diabetes mellitus of obese rats: impairment in adipocyte-beta-cell relationships. Proc Natl Acad Sci USA 91:10878-10882.
26. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, Chen M, Tran T, Lopez E, Lu JY, and Li XN, et al. (2011) AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS One 6:e27270.
27. Mancini AD and Poitout V (2015) GPR40 agonists for the treatment of type 2 diabetes: life after 'TAKing' a hit. Diabetes Obes Metab 17:622-629.
28. Matthews DR, Cull CA, Stratton IM, Holman RR, and Turner RC; UK Prospective Diabetes Study (UKPDS) Group (1998) UKPDS 26: Sulphonylurea failure in noninsulin-dependent diabetic patients over six years. Diabet Med 15:297-303.
29. Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, and Odaka H (2009) Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice. Br J Pharmacol 157:415-426.
30. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, Tanaka H, Nakata M, Yano T, Shimakawa K, and Taketomi S, et al. (2009) Overexpression of GPR40 in pancreatic beta-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067-1076.
31. Naik H, Vakilynejad M, Wu J, Viswanathan P, Dote N, Higuchi T, and Leifke E (2012) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of the GPR40 agonist TAK-875: results from a double-blind, placebo-controlled single oral dose rising study in healthy volunteers. J Clin Pharmacol 52:1007-1016.
32. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, Tsujihata Y, Ito R, Harada A, Takeuchi K, and Suzuki N, et al. (2010) Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med Chem Lett 1:290-294.
33. Negoro N, Sasaki S, Mikami S, Ito M, Tsujihata Y, Ito R, Suzuki M, Takeuchi K, Suzuki N, and Miyazaki J, et al. (2012) Optimization of (2, 3-dihydro-1-benzofuran-3-yl) acetic acids: discovery of a non-free fatty acid-like, highly bioavailable G protein-coupled receptor 40/free fatty acid receptor 1 agonist as a glucosedependent insulinotropic agent. J Med Chem 55:3960-3974.
34. Poitout V and Robertson RP (2002) Minireview: Secondary beta-cell failure in type 2 diabetes-a convergence of glucotoxicity and lipotoxicity. Endocrinology 143:339-342.
35. Portha B, Blondel O, Serradas P, McEvoy R, Giroix MH, Kergoat M, and Bailbe D (1989) The rat models of non-insulin dependent diabetes induced by neonatal streptozotocin. Diabete Metab 15:61-75.
36. Rendell M (2004) The role of sulphonylureas in the management of type 2 diabetes mellitus. Drugs 64:1339-1358.
37. Rustenbeck I (2002) Desensitization of insulin secretion. Biochem Pharmacol 63:1921-1935.
38. Sakuma K, Yabuki C, Maruyama M, Abiru A, Komatsu H, Negoro N, Tsujihata Y, Takeuchi K, Habata Y, and Mori M (2015) The individual roles of inositol triphosphate and diacylglycerol, downstream messengers of FFAR1/GPR40 produced by fasiglifam on the glucose-dependent insulinotropic effect. Diabetes 64(Suppl 1):A574-A602.
39. Shapiro H, Shachar S, Sekler I, Hershfinkel M, and Walker MD (2005) Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem Biophys Res Commun 335:97-104.
40. Srivastava A, Yano J, Hirozane Y, Kefala G, Gruswitz F, Snell G, Lane W, Ivetac A, Aertgeerts K, and Nguyen J, et al. (2014) High-resolution structure of the human GPR40 receptor bound to allosteric agonist TAK-875. Nature 513:124-127.
41. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, Zhou C, Lin S, Salituro G, Meinke P, and Mosley R, et al. (2008) Selective small-molecule agonists of G proteincoupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57:2211-2219.
42. Tokuyama Y, Sturis J, De Paoli AM, Takeda J, Stoffel M, Tang J, Sun X, Polonsky KS, and Bell GI (1995) Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes 44:1447-1457.
43. Tsujihata Y, Ito R, Suzuki M, Harada A, Negoro N, Yasuma T, Momose Y, and Takeuchi K (2011) TAK-875, an orally available G protein-coupled receptor 40/free fatty acid receptor 1 agonist, enhances glucose-dependent insulin secretion and improves both postprandial and fasting hyperglycemia in type 2 diabetic rats. J Pharmacol Exp Ther 339:228-237.
44. Wajchenberg BL (2007) beta-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 28:187-218.
45. Winzell MS and Ahrén B (2007) G-protein-coupled receptors and islet functionimplications for treatment of type 2 diabetes. Pharmacol Ther 116:437-448.
46. Yabe D and Seino Y (2014) Dipeptidyl peptidase-4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe? J Diabetes Investig 5:475-477.
47. Yabuki C, Komatsu H, Tsujihata Y, Maeda R, Ito R, Matsuda-Nagasumi K, Sakuma K, Miyawaki K, Kikuchi N, and Takeuchi K, et al. (2013) A novel antidiabetic drug, fasiglifam/TAK-875, acts as an ago-allosteric modulator of FFAR1. PLoS One 8:e76280.
48. Yang M, Chisholm JW, Soelaiman S, and Shryock JC (2010) Sulfonylureas uncouple glucose-dependence for GPR40-mediated enhancement of insulin secretion from INS-1E cells. Mol Cell Endocrinol 315:308-313.
49. Zawalich WS, Zawalich KC, and Rasmussen H (1993) Influence of glucagon-like peptide-1 on beta cell responsiveness. Regul Pept 44:277-283.
50. Zhao YF, Pei J, and Chen C (2008) Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J Endocrinol 198:533-540.